Exposure to Infliximab During Pregnancy: Post-Marketing Experience-Reference-Cited by-同舟云学术

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Published:2019-11-01 Issue:2 Volume:43 Page:147-161
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Geldhof Anja^ORCID,Slater Jennifer,Clark Michael,Chandran Urmila,Coppola Danielle

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-019-00881-8.pdf

Reference79 articles.

1. Fonager K, Sørensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn’s disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426–30.

2. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol. 1984;6:211–6.

3. Lin HC, Chen SF, Lin HC, et al. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study. Ann Rheum Dis. 2010;69:715–7.

4. Bobotsis R, Gulliver WP, Monaghan K, et al. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol. 2016;175:464–72.

5. Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–9.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consenso para la gestión de riesgo en la prescripción de terapias biológicas o de antirreumáticos sintéticos con blanco dirigido: Asociación Colombiana de Reumatología 2023;Revista Colombiana de Reumatología;2024-04

2. Safety of biologic agents for the management of rheumatic diseases during pregnancy;Current Opinion in Rheumatology;2024-03-11

3. Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance;British Journal of Dermatology;2023-08-18

4. Neuroimmunological Disorders;Neurologic Clinics;2023-05

5. Elevated cord levels of ustekinumab following its use in the treatment of Crohn's disease in pregnancy;Obstetric Medicine;2022-11-07